Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
165 hedge funds and large institutions have $1.88B invested in Sage Therapeutics in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 65 increasing their positions, 47 reducing their positions, and 16 closing their positions.
98.83% more ownership
Funds ownership: 0% → 98.83% (+99%)
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
38% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 47
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
9% more capital invested
Capital invested by funds: $1.72B → $1.88B (+$154M)
9% more funds holding
Funds holding: 152 → 165 (+13)
7% less call options, than puts
Call options by funds: $29.4M | Put options by funds: $31.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$54.5M |
| 2 |
Bank of New York Mellon
New York
|
+$27M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.95M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$56.3M |
| 2 |
Millennium Management
New York
|
-$21M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$17.1M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$14.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.5M |
SAGE Hedge Fund Activity: Q4 2016 in Review
165 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2016, worth a combined $1.88B — up 9% from $1.72B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SAGE positions and 16 closed out — a net gain of 15 holders — while 65 added to existing stakes and 47 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $54.5M. The largest seller was Citadel Advisors, cutting an estimated $56.3M.
- 165 institutional investors held Sage Therapeutics (SAGE) as of Q4 2016, up from 152 in Q3 2016.
- Funds reported $1.88B of Sage Therapeutics stock for Q4 2016, up 9% quarter-over-quarter.
- 31 funds opened new Sage Therapeutics positions in Q4 2016 and 16 closed out, a net change of +15 holders.
- The largest Sage Therapeutics buyer in Q4 2016 was T. Rowe Price Associates, an estimated $54.5M added.
- The largest Sage Therapeutics seller in Q4 2016 was Citadel Advisors, an estimated $56.3M sold.
Based on aggregated 13F filings for Q4 2016.